Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)– Hagens Berman
SAN FRANCISCO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31 ...
Objective To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular ...
We constructed a CNN based on U-Net, and every CNN block in U-Net ... The first set is a publicly available OCT database20 consisting of four categories; normal, drusen, CNV and diabetic macular edema ...
Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...
Perspective from Bridget Boamah Appiah, OD, FAAO OCT angiography alone demonstrated superior sensitivity in detecting glaucomatous changes in the optic disc and macula compared with OCT and OCT ...
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback